BFQ

IBANDRONATE

Find entries where: BFQ

is present as a standalone ligand in 4 entries

as a non-polymer is covalently linked to polymer or other heterogen groups 1 entries

Find related ligands:

Similar Ligands (Stereospecific)

Similar Ligands (Quick Screen)

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	IBANDRONATE
Synonyms	[1-HYDROXY-3-(METHYL-PENTYL-AMINO)-1-PHOSPHONO-PROPYL]-PHOSPHONIC ACID
Identifiers	[1-hydroxy-3-(methyl-pentyl-amino)-1-phosphono-propyl]phosphonic acid
Formula	C₉ H₂₃ N O₇ P₂
Molecular Weight	319.229
Type	NON-POLYMER
Isomeric SMILES	CCCCC[N@](C)CCC(O)(P(=O)(O)O)P(=O)(O)O
InChI	InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)
InChIKey	MPBVHIBUJCELCL-UHFFFAOYSA-N

Chemical Details
Formal Charge	0
Atom Count	42
Chiral Atom Count	1
Bond Count	41
Aromatic Bond Count	0

Drug Info: DrugBank

DrugBank ID	DB00710
Name	Ibandronate
Groups	investigational approved
Description	Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to [zoledronic acid], [minodronic acid], and [risedronic acid].[A203111,A203138] It is used to prevent and treat postmenopausal osteoporosis.[L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs.[A203138] Ibandronate was granted FDA approval on 16 May 2003.[L13805]
Synonyms	Ibandronate Ibandronic acid Ibandronate sodium ácido ibandrónico
Brand Names	Bondronat Ibandronic Acid Sandoz Ibandronate Sodium Ibandronic Acid Accord Boniva Bondenza Ibandronate sodium Ibandronic Acid Teva Bonviva Iasibon
Indication	For the treatment and prevention of osteoporosis in postmenopausal women.[L13805,L13808]
Categories	Agents Causing Muscle Toxicity Bisphosphonates Bone Density Conservation Agents Drugs Affecting Bone Structure and Mineralization Drugs for Treatment of Bone Diseases Musculo-Skeletal System Organophosphonates Organophosphorus Compounds Potential QTc-Prolonging Agents QTc Prolonging Agents
ATC-Code	M05BA06 M05BB09
CAS number	114084-78-5

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
Hydroxylapatite	-	unknown	antagonist
Geranylgeranyl pyrophosphate synthase	MEKTQETVQRILLEPYKYLLQLPGKQVRTKLSQAFNHWLKVPEDKLQIII...	unknown	inhibitor
Farnesyl pyrophosphate synthase	MPLSRWLRSVGVFLLPAPYWAPRERWLGSLRRPSLVHGYPVLAWHSARCW...	unknown	inhibitor

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682